Open AccessGiant malignant gastrointestinal stromal tumors: Recurrence and effects of treatment with STI-571
Author(s) -
Teng-Wei Chen,
Hsiao-Dung Liu,
Rong-Yaun Shyu,
Jyh-Cherng Yu,
Ming-Lang Shih,
Tzu-Ming Chang,
Chung-Bao Hsieh
Publication year - 2005
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v11.i2.260
Subject(s) - medicine , imatinib mesylate , retrospective cohort study , survival rate , surgical margin , imatinib , gastroenterology , resection margin , stromal tumor , tyrosine kinase inhibitor , gist , log rank test , stromal cell , survival analysis , surgery , oncology , cancer , resection , myeloid leukemia
Malignant gastrointestinal stromal tumors (GISTs) are rare. Tumors larger than 10 cm tend to recur earlier: the larger the volume of the tumor, the worse the prognosis. We hypothesized that treatment with imatinib mesylate (Gleevec; STI-571), a c-kit tyrosine kinase inhibitor, as palliative therapy would prolong the survival of patients with recurrent giant malignant GISTs after resection.